Diabetes and Hypertension: A Position Statement by the American Diabetes Association

Сахарный диабет и артериальная гипертензия: позиционное заявление Американской диабетической ассоциации
Ian H. de Boer, Sripal Bangalore, Athanase Bénétos, Andrew M. Davis, Erin D. Michos, Paul Muntner, Peter Rossing, Sophia Zoungas, George L. Bakris
2017-08-14

antihypertensive therapyatherosclerotic cardiovascular diseaseblood pressure controlhypertension in diabetesmicrovascular complications
Hypertension is common among patients with diabetes, with the prevalence depending on type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and the presence of kidney disease, among other factors (1-3). Furthermore, hypertension is a strong risk factor for atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications. ASCVDddefined as acute coronary syndrome, myocardial infarction (MI), angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origindis the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. Numerous studies have shown that antihypertensive therapy reduces ASCVD events, heart failure, and microvascular complications in people with diabetes (4-8). Large benefits are seen when multiple risk factors are addressed simultaneously (9). There is evidence that ASCVD morbidity and mortality have decreased for people with diabetes since 1990 (10,11) likely due in large part to improvements in blood pressure control This Position Statement is intended to update the assessment and treatment of hypertension among people with diabetes, including advances in care since the American Diabetes Association (ADA) last published a Position Statement on this topic in 2003 (3).
1
Addressing multiple cardiovascular risk factors simultaneously produces substantial benefits for people with diabetes.
2
Antihypertensive therapy reduces atherosclerotic cardiovascular disease events, heart failure, and microvascular complications among individuals with diabetes.
3
Declines in atherosclerotic cardiovascular disease morbidity and mortality among people with diabetes since 1990 may be largely attributable to improved blood pressure control; the ADA statement updates hypertension assessment and treatment recommendations.
4
Hypertension is common in people with diabetes, with prevalence varying by diabetes characteristics, demographics, body mass index, glycemic control, and kidney disease.
5
Hypertension substantially increases the risk of atherosclerotic cardiovascular disease, heart failure, and microvascular complications in people with diabetes.

hypertension among people with diabetes

assessment and treatment of hypertension, including its effects on ASCVD, heart failure, and microvascular complications

Publication Details
Publication Date
2017-08-14
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Ian H. de Boer
Sripal Bangalore
Athanase Bénétos
Andrew M. Davis
Erin D. Michos
Paul Muntner
Peter Rossing
Sophia Zoungas
George L. Bakris
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%